Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 250 movers: Indivior profit warning weighs on index
(Sharecast News) - FTSE 250 (MCX) 20,646.12 -0.73% Pharma group Indivior saw shares plummet on Tuesday after it issued a profit warning for 2024 on the back of "adverse market dynamics" affecting its Sublocade treatment, and announced it was discontinuing its Perseris product.
Indivior said it expects to generate $1,150-1,215m in revenues for 2024, down from earlier guidance of $1,240-1,330m, with adjusted operating profits pencilled in at $285-320m, compared with previous projections of $330-380m.
The downgrade was mainly due to lower expected sales of Sublocade, its treatment of moderate to severe opioid use disorder.
"Despite positive early performance trends at the start of the second quarter, Sublocade net revenue has continued to be impacted more than we expected by a combination of transitory factors, primarily the elimination of COVID emergency measures related to automatic Medicaid coverage renewals," explained chief executive Mark Crossley.
"Furthermore, as we look to the second half of the year, the U.S. government has extended renewal allowances for certain States which will further delay the annualisation of this significant headwind."
Meanwhile, the company said it was discontinuing the sales and marketing of Perseris, previously expected to generated $55-65m in sales this year, which it said was in the "best interests of shareholders due to the highly competitive market and impending changes that are expected to intensify payor management in the treatment category".
Indivior said that an analysis of forthcoming changes in the market suggests that "there is no longer a path forward for Perseris that is financially viable". The company will continue to supply the product for the foreseeable future to avoid disruption to patient care but will no longer deploy a dedicated sales force, which will result in 130 job losses. The company will book a charge of $65m from these changes.
Indivior also revealed it was paying $85m to settle antitrust claims ahead of an expected trial date on 15 July - bringing an end to litigation that has been pending since 2020.
Recruiter PageGroup warned on profits on Tuesday, citing geopolitical and macroeconomic uncertainty.
In a trading update for the second quarter, the company said gross profit fell 12% versus the same period a year earlier to £224m. PageGroup said it continued to see tough market conditions in the majority of its markets, with no immediate signs of improvement.
"As clients' recruitment budgets have tightened, they have become more risk averse which has slowed the recruitment process," it said. "Although salary levels remain strong, offers made to candidates were not as elevated as they were in 2022 and early 2023."
The recruiter also said it had seen a slower end to the quarter, with June gross profits down 18% on 2023 and a softening of activity levels through the quarter, particularly in terms of new jobs registered and number of interviews.
PageGroup said conversion of interviews to accepted offers remains the most significant challenge due to subdued client and candidate confidence.
"Given the weaker than expected trading in June, recent increased geopolitical and macroeconomic uncertainty and consequently a more cautious view for H2, the board now expects full year 2024 operating profit to be in the region of £60m," it said. This is down from £118.8m last year and below estimates of £90m.
Market Movers
FTSE 250 - Risers
Aston Martin Lagonda Global Holdings (AML) 159.10p 5.29% Trustpilot Group (TRST) 235.00p 3.30% Moonpig Group (MOON) 199.60p 2.89% Playtech (PTEC) 516.00p 1.78% Diversified Energy Company (DEC) 1,108.00p 1.74% Ocado Group (OCDO) 351.90p 1.73% Hill and Smith (HILS) 2,110.00p 1.69% JPMorgan Japanese Inv Trust (JFJ) 555.00p 1.65% Discoverie Group (DSCV) 693.00p 1.61% Auction Technology Group (ATG) 477.00p 1.49%
FTSE 250 - Fallers
Indivior (INDV) 720.50p -38.99% Pagegroup (PAGE) 394.00p -6.77% Hays (HAS) 89.45p -5.49% Hiscox Limited (DI) (HSX) 1,219.00p -3.79% OSB Group (OSB) 467.80p -3.74% Ibstock (IBST) 180.80p -3.21% North Atlantic Smaller Companies Inv Trust (NAS) 3,950.00p -3.19% W.A.G Payment Solutions (WPS) 63.20p -3.07% XPS Pensions Group (XPS) 313.00p -2.80% Victrex plc (VCT) 1,126.00p -2.76%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.